Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell and gene therapy manufacturing

- PMLiVE

Novartis’ Entresto launched in UK

Drug was first CHF therapy to show an improvement over ACE inhibitors

Novartis sets sights on connected inhaler

Plans 2019 launch for Qualcomm-partnered device

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

- PMLiVE

Baxalta and CTI complete filing for Jakafi rival in US

Myelofibrosis candidate pacritinib aiming for accelerated approval

Novartis building

Novartis’ Entresto gets EU green light

Winsapproval for symptomatic chronic heart failure with reduced ejection fraction

Novartis building

Novartis’ Cosentyx cleared for wider use in Europe

Approved for psoriatic arthritis and ankylosing spondylitis

- PMLiVE

FDA accepts Sandoz filing for biosimilar Neulasta

Theversion of Amgen's blockbuster will have a 10-month review period

CAR-T cancer therapy passes milestone

Belgianbiotech Celyad's cancer immunotherapy will now be tested at higher doses

- PMLiVE

FDA approves Exelixis/Genentech’s melanoma combo Cotellic

Willprovide the first direct competition to Novartis' Mekinist in the US

- PMLiVE

Novartis curates interactive history of medicine exhibition

Beautiful Medicine highlights nature's role in the past and future ofdevelopment

- PMLiVE

Novartis’ Cosentyx off to a flyer in psoriasis

Year-to-date sales reach $140m for recently approved drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links